Comparison of the inhibition of recombinant and native heme oxygenase-1 (HO-1) activity by the imidazoledioxolane compound QC-15

Main Article Content

Nick Stone

Abstract

Recombinant full-length and truncated forms of human heme oxygenase-1 (hHO-1) were compared with their native, microsomal HO-1 counterpart from rat spleen tissue, with respect to their inhibition by the imidazole-dioxolane HO inhibitor QC-15. Rat native HO-1 was maximally inhibited to the greatest extent (7.53 ± 1.51% of control activity), as compared to recombinant, full-length hHO-1 (55.55 ± 6.08%), and also truncated hHO-1 (72.17 ± 5.94%). The greater susceptibility of native HO-1 to QC-15 inhibition may be attributed to the presence of its C-terminal transmembrane domain (CTD) and its anchoring into the endoplasmic reticulum (ER). If so, membrane-anchored, recombinant, full-length hHO-1 may replace the current HO-1 microsomal model derived from rat spleen, in future in vitro inhibition studies. A better understanding of HO-1 inhibitors like QC-15 may lead to chemotherapeutics that prevent tumour cells from taking advantage of the cytoprotective nature of the HO system.

Article Details

Section
Articles
Author Biography

Nick Stone, Queen’s University, Kingston, ON, Canada

Supervised by: Brian McLaughlin and Kanji Nakatsu, Department of Biomedical and Molecular Sciences Botterell Hall, Queen’s University, Kingston, ON, Canada